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Background Findings Discussion
Postoperative nausea and vomiting (PONV) is a common complication 
following surgery. It remains the most important determinant of length of stay 
and leading cause of dissatisfaction in anesthesia.4 Females undergoing 
gynecological laparoscopic surgery have the highest rates.8 Apfel’s baseline risk 
factors for PONV include female gender, history of motion sickness and/or 
PONV, non-smoking status and administration of postoperative opioids.1
Propofol has antiemetic properties and Gan’s evidence supports the use of an 
intraoperative low-dose infusion to reduce baseline risk factors for PONV.6 This 
project aims to describe the rates of intraoperative low-dose propofol 
infusions in female patients undergoing gynecological surgery and baseline 
characteristics associated with its use. 
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Methods
• A retrospective, observational evidence-based practice project was 
conducted at Providence Sacred Heart Medical Center (PSHMC) and 
Providence Holy Family Hospital (PHFH) in Spokane, WA.
• CIRC approval was obtained by the facility and IRB exemption granted. All 
patient data was securely extracted by a Providence sponsor and stored in 
a HIPAA compliant REDCap database. Patient data was fully de-identified.
• Inclusion criteria consisted of adult patients ≥18 to 90 years of age 
undergoing general anesthesia with volatile anesthetics in gynecological 
surgeries that were hospitalized for at least 24 hours and no more than 14 
days at PSHMC and PHFH from January 2014 to December 2019. Patients 
receiving intraoperative low-dose propofol infusions of ≤25 mcg/kg/min 
were identified. 
• Exclusion criteria consisted of patients <18 and >90 years of age, infusions 
>25 mcg/kg/min, and any patient hospitalized for <24 hours and >14 days.
• 24-hour PONV outcome was determined by PACU nurse assessment of 
PONV in EPIC or administration of antiemetic medication in the EMR. 
• Statistical data analysis was conducted and stratified by the number of 
Apfel risk factors.
• Univariate and bivariate analysis were conducted on categorical and 
continuous data.
• Multivariable analysis was conducted through binary logistic regression 
controlling for variables that contributed to the use of a propofol infusion.
This multi-year evidence-based practice project examined 499 cases and found 
that intraoperative low-dose propofol infusions were used 45 times accounting 
for 9% of the total sample. Current research literature supports the utilization of 
low-dose propofol infusions for patients at high-risk of developing PONV. 3,6,7
Age, BMI, case duration, ASA status, smoking status and post-op opioids did not 
influence whether a patient received an intraoperative low-dose propofol 
infusion. Bivariate analysis only showed a statistical significance with history of 
PONV (P=0.04). Similar findings were demonstrated in a multivariable model. 
This project focused on a clinically vulnerable population with low-dose propofol 
infusions and PONV. Overall rates for 24-hour PONV in this patient sample were 
76% (N=499). 24-hour rates for patients that received an infusion were 84% 
(n=45) which may be explained by treatment by indication in this high-risk 
sample. 
Overall, results from this project identify areas for care improvement and CRNA 
education.
Variable Value Mean Stdev*
Age Years 57 14
Body Mass Index Kg/m2 36 11
Case Duration Minutes 169 58
n %
Sex Female 499 100%




Smoking Status 76 15%
History of PONV 106 21%
Post-op Opioids 377 76%
Case Type Elective 480 96%
Urgent 16 3%
Emergent 2 0.4%
Surgical Procedure                 
Robotic Assisted Hysterectomy 
Hysterectomy Abdominal 
Robotic Assisted Hysterectomy w/ Staging
Robotic Assisted Hysterectomy w/ BSO
Hysterectomy Vaginal 







Table 1. Patient Demographics & Clinical Characteristics (N=499)
Table 2. Variables Associated with Low-Dose Propofol Infusion Use
Table 3. Independent Risk Factors Associated with 
Low-Dose Propofol Infusion Use
Figure 1. Low-Dose Propofol Infusion Use (N=499)
Variable Odds Ratio 95% CI* P-value
Age 0.98 0.97-1.02 0.82
Smoking Status 1.06 0.45-2.48 0.90
History of PONV 1.94 1.00-3.77 0.05
Post-op Opioids 1.46 0.65-3.28 0.35
Figure 2. 24-Hour Proportion of PONV (N=499) 
45, 9%
454, 91%
Propofol Yes Propofol No
380, 76%
119, 24%
PONV Yes PONV No
No Infusion (n=454) Infusion (n=45) 
Mean Stdev Mean Stdev P-value
Age 56.95 13.82 55.93 13.87 0.64
Body Mass Index 35.62 11.37 35.55 12.53 0.97
Case Duration 168.66 57.34 170.38 60.9 0.85
n % n % P-value
Smoking Status 69 15% 7 16% 0.95
History of PONV 91 20% 15 33% 0.04
Post-op Opioid 340 75% 37 82% 0.27
(n=429) % (n=42) % P-value
ASA 3 & 4 187 44% 14 33% 0.20 *ASA: American Society of Anesthesiologists Physical Status Classification; *Stdev: Standard 
Deviation; *CI: Confidence Interval 
